NOV03治疗与睑板腺功能障碍相关的干眼病:随机3期GOBI研究结果
这项为期8周的多中心随机双盲生理盐水对照3期研究纳入599例与睑板腺功能障碍相关的干眼病患者,评估NOV03(全氟己基辛烷)滴眼液与低渗生理盐水每日4次的效果。第8周时,NOV03在总角膜荧光素染色评分和眼干涩评分改善上均显著优于生理盐水,所有关键次要终点也显著 favoring NOV03,且耐受性良好,无严重眼部不良事件。
要点
- 第8周总角膜荧光素染色评分改善NOV03显著优于生理盐水,LS均值治疗差异-0.97(95%CI:-1.40,-0.55)。
- 第8周眼干涩VAS评分改善NOV03显著优于生理盐水,LS均值治疗差异-7.6(95%CI:-11.8,-3.4)。
- 多数眼部不良事件为轻度,无严重眼部不良事件,仅1例因眼刺激停止NOV03。
核心结论
- 在与睑板腺功能障碍相关的干眼病患者中,NOV03较生理盐水在干眼体征和症状上显示出统计学显著且临床有意义的改善,且耐受性良好。
研究设计与样本
- 8周、3期、多中心、随机、双盲、生理盐水对照研究,纳入599例随机分组患者,597例接受治疗(NOV03组n=303,生理盐水组n=294)。
主要发现
- 第8周总角膜荧光素染色评分(tCFS)较基线改善NOV03显著优于生理盐水(P<0.001),LS均值治疗差异-0.97(95%CI:-1.40,-0.55)。
- 第8周眼干涩VAS评分较基线改善NOV03显著优于生理盐水(P<0.001),LS均值治疗差异-7.6(95%CI:-11.8,-3.4)。
- 所有关键次要终点均显著 favoring NOV03(P<0.01):第2周眼干涩VAS评分LS均值治疗差异-4.7(95%CI:-8.2,-1.2),第2周tCFS -0.6(95%CI:-0.9,-0.2),第8周眼灼烧或刺痛VAS评分-5.5(95%CI:-9.5,-1.6),第8周中央角膜荧光素染色评分-0.2(95%CI:-0.4,-0.1)。
关键数值与推荐
- 纳入标准:年龄≥18岁,干眼病史≥6个月,泪膜破裂时间≤5秒,Schirmer I试验(无麻醉)评分≥5 mm,睑板腺功能障碍评分≥3(0-15量表),总角膜荧光素染色评分≥4且≤11(0-15 NEI量表)。
- 患者按1:1随机分配至NOV03或低渗(0.6%)生理盐水,每日4次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the efficacy and safety of NOV03 (perfluorohexyloctane) ophthalmic drop in patients with dry eye disease (DED) associated with meibomian gland dysfunction (MGD). DESIGN: Eight-week, phase 3, multicenter, randomized, double-masked, saline-controlled study. PARTICIPANTS: Adults ≥ 18 years with a history of DED for ≥ 6 months, tear film breakup time of ≤ 5 seconds, Schirmer I test (without anesthesia) score ≥ 5 mm, MGD score ≥ 3 (0-15 scale), and total corneal fluorescein staining (tCFS) score ≥ 4 and ≤ 11 (0-15 National Eye Institute [NEI] scale). METHODS: Patients were randomized 1:1 to NOV03 or hypotonic (0.6%) saline 4 times daily. MAIN OUTCOME MEASURES: The primary sign and symptom end points were change from baseline in tCFS and eye dryness score (0-100 visual analog scale [VAS]) at week 8. Key secondary end points were change from baseline in eye dryness score at week 2, tCFS at week 2, eye burning or stinging score (0-100 VAS) at week 8, and central corneal fluorescein staining (cCFS; 0-3 NEI scale) at week 8. RESULTS: Of the 599 patients randomized, 597 were treated (NOV03, n = 303; saline, n = 294). At week 8, improvement from baseline was significantly greater (P < 0.001) with NOV03 versus saline for tCFS (least square [LS] mean treatment difference, -0.97; 95% confidence interval [CI]: -1.40, -0.55) and VAS dryness score (-7.6; 95% CI: -11.8, -3.4). Improvement from baseline also significantly (P < 0.01) favored NOV03 on all key secondary end points: LS mean treatment difference (95% CI) was -4.7 (-8.2, -1.2) for VAS dryness score at week 2, -0.6 (-0.9, -0.2) for tCFS at week 2, -5.5 (-9.5, -1.6) for VAS burning or stinging score at week 8, and -0.2 (-0.4, -0.1) for cCFS at week 8. Most ocular adverse events (AEs) were mild in severity; no serious ocular AEs occurred. One patient discontinued NOV03 because of an AE (eye irritation). CONCLUSIONS: In patients with DED associated with MGD, NOV03 demonstrated statistically significant and clinically meaningful improvements versus hypotonic saline in signs and symptoms of DED and was well tolerated. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
引用
- Tauber J, Berdy GJ, Wirta DL, et al. NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study. Ophthalmology. 2022. PMID: 36574848. doi:10.1016/j.ophtha.2022.12.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。